Beijing Hotgen Biotech Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 303.04 million compared to CNY 2,023.08 million a year ago. Revenue was CNY 307.01 million compared to CNY 2,045.69 million a year ago.

Net income was CNY 84.77 million compared to CNY 814.78 million a year ago. Basic earnings per share from continuing operations was CNY 0.95 compared to CNY 8.85 a year ago. Diluted earnings per share from continuing operations was CNY 0.95 compared to CNY 8.85 a year ago.